Skip to main content

Advertisement

Table 3 Efficacy of a single oral dose of Simparica Trio™ and afoxolaner+ milbemycin oxime against natural infestations with Ctenocephalides felis, Ctenocephalides canis, Pulex irritans and Archaeopsylla erinacei on dogs presented as veterinary patients in Europe

From: Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Treatment groupStudy dayC. felisC. canisP. irritansA. erinacei
Mean flea count% EfficacyMean flea count% EfficacyMean flea count% EfficacyMean flea count% Efficacy
Simparica Trio™− 1 or 012.4 8.9 4.4 2.0 
14 ± 50.397.6010001000100
30 ± 50.298.90100099.70100
Afoxolaner + Milbemycin oxime− 1 or 09.6 7.2 6.1 6.0 
14 ± 50.596.201000.297.81.389.7
30 ± 50.298.1010001000100.0
  1. Note: Before treatment administration (on study day − 1 or 0) the number of dogs in the Simparica Trio™ and afoxolaner + milbemycin oxime groups infected with each species was 139 and 76 for C. felis, 33 and 17 for C. canis, 34 and 16 for P. irritans and 2 and 3 for A. erinacei, respectively